Skip to main content
Bradley Haverkos, MD, Oncology, Aurora, CO

BradleyMichaelHaverkosMD

Oncology Aurora, CO

Physician

Dr. Haverkos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Haverkos' full profile

Already have an account?

  • Office

    1665 Aurora Ct
    Fl 2
    Aurora, CO 80045
    Phone+1 720-848-8698
    Fax+1 720-848-1786

Education & Training

  • Ohio State University College of Medicine
    Ohio State University College of MedicineM.M.S., 2013 - 2015
  • Ohio State University Hospital
    Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2009 - 2012
  • Wright State University
    Wright State UniversityM.P.H., 2005 - 2009
  • Wright State University Boonshoft School of Medicine
    Wright State University Boonshoft School of MedicineClass of 2009
  • Miami University
    Miami UniversityB.A., Major: Psychology; Minor: Neuroscience, 1999 - 2003

Certifications & Licensure

  • NE State Medical License
    NE State Medical License 2020 - 2026
  • CO State Medical License
    CO State Medical License 2015 - 2025
  • KS State Medical License
    KS State Medical License 2021 - 2025
  • NM State Medical License
    NM State Medical License 2020 - 2025
  • WY State Medical License
    WY State Medical License 2020 - 2025
  • OH State Medical License
    OH State Medical License 2012 - 2016
  • IL State Medical License
    IL State Medical License 2009 - 2012

Awards, Honors, & Recognition

  • Boonshoft Physician Leadership Development Scholarship Wright State University, 2009
  • Outstanding Senior Medical Student in Internal Medicine 2009
  • College of Arts and Science Scholarship Miami University, 2002
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Epstein-Barr Virus Type-2 Infects T-cells and Induces B-cell Lymphomagenesis in Humanized Mice  
    Bradley Haverkos, Zenggang Pan, mBio
  • Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas  
    Haverkos, B., Huang, Y., Gru, A., Pancholi, P., Freud, A., Mishra, A., Ruppert, A., Baiocchi, R., & Porcu, P., IJC, 1/1/2017
  • A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation  
    Haverkos, B. Huang, Y., Elder, P., O’Donnell, L., Scholl, D., Whittaker, B., Vasu, S., Penza, S., Andrtisos, L., Devine, S., & Jaglowski, S., BMT, 1/1/2017
  • Join now to see all

Abstracts/Posters

  • Dose Reduction or Omission of Vinca Alkaloids during Initial Chemotherapy Treatment Does Not Impact Outcomes in Patients with Lymphoma
    Brad M. Haverkos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
    Brad M. Haverkos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
    Brad M. Haverkos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • CNS Lymphoma 
    1/28/2017
  • Cutaneous Lymphomas 
    University of Colorado - 1/24/2017
  • Aggressive Non-Hodgkin Lymphoma. 
    1/13/2017
  • Join now to see all

Other

Press Mentions

  • Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-Val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
    Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-Val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021December 13th, 2021
  • The Making of a Model for AML
    The Making of a Model for AMLDecember 3rd, 2018